DRG Market Assessment 보고서
질환 개요 및 예측, 역학 인텔리전스, 바이오시밀러 인텔리전스, China In-depth 등 폭넓은 시장 인텔리전스를 확인해 보세요.
Immune Checkpoint Inhibitors in Bladder Cancer, NSCLC, and Malignant Melanoma | Access & Reimbursement | US | 2019
Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications, including non-small-cell lung cancer (NSCLC), malignant melanoma, and bladder cancer. As premium-…
Immune Checkpoint Inhibitors | Access and Reimbursement | Top Five European Markets | 2019
Immune checkpoint inhibitors, including Bristol-Myers Squibb’s Opdivo, Merck & Co.’s Keytruda, and Roche’s Tecentriq, are revolutionizing the therapeutic strategies for several cancers. This…